Cargando…

An estriol-eluting pessary to treat pelvic organ prolapse

Pelvic organ prolapse affects up to 50% of parous women. Commonly used treatment options have unwelcome attributes; pessaries can cause erosion and estrogen creams need to be applied frequently, which is inconvenient and difficult to administer. This study involved the development of an estriol-rele...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Jingjunjiao, Zidan, Ghada, Seyfoddin, Ali, Tong, Stephen, Brownfoot, Fiona C., Chowdary, Prathima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681886/
https://www.ncbi.nlm.nih.gov/pubmed/36414726
http://dx.doi.org/10.1038/s41598-022-23791-9
_version_ 1784834725912772608
author Long, Jingjunjiao
Zidan, Ghada
Seyfoddin, Ali
Tong, Stephen
Brownfoot, Fiona C.
Chowdary, Prathima
author_facet Long, Jingjunjiao
Zidan, Ghada
Seyfoddin, Ali
Tong, Stephen
Brownfoot, Fiona C.
Chowdary, Prathima
author_sort Long, Jingjunjiao
collection PubMed
description Pelvic organ prolapse affects up to 50% of parous women. Commonly used treatment options have unwelcome attributes; pessaries can cause erosion and estrogen creams need to be applied frequently, which is inconvenient and difficult to administer. This study involved the development of an estriol-releasing pessary utilising 3D printing molds. We incorporated varying amounts of estriol (1%, 10% and 15%) into the silicone pessary. We optimised the mechanical aspects of the pessary so it had a similar strength to commercially available pessaries. We investigated estriol release from the pessary over 3 months. We explored possible interactions between the drug and polymers via FTIR. The MED-4870 silicone ring with similar mechanical strength to pessaries currently used to treat pelvic organ prolapse. The medical pessaries present a sustained release in simulated vaginal fluid over 3 months. The pessary with 10% estriol delivered the optimal dose at 0.8 mg each week. Mechanical strength of this pessary showed no difference after emersion in simulated vaginal fluid for 3-month, supporting the long-term application. An estriol-loaded pessary was successfully developed to treat pelvic organ prolapse with sustained release of estriol over 3 months. This pessary provides promising potential to treat pelvic organ prolapse and vaginal atrophy.
format Online
Article
Text
id pubmed-9681886
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-96818862022-11-24 An estriol-eluting pessary to treat pelvic organ prolapse Long, Jingjunjiao Zidan, Ghada Seyfoddin, Ali Tong, Stephen Brownfoot, Fiona C. Chowdary, Prathima Sci Rep Article Pelvic organ prolapse affects up to 50% of parous women. Commonly used treatment options have unwelcome attributes; pessaries can cause erosion and estrogen creams need to be applied frequently, which is inconvenient and difficult to administer. This study involved the development of an estriol-releasing pessary utilising 3D printing molds. We incorporated varying amounts of estriol (1%, 10% and 15%) into the silicone pessary. We optimised the mechanical aspects of the pessary so it had a similar strength to commercially available pessaries. We investigated estriol release from the pessary over 3 months. We explored possible interactions between the drug and polymers via FTIR. The MED-4870 silicone ring with similar mechanical strength to pessaries currently used to treat pelvic organ prolapse. The medical pessaries present a sustained release in simulated vaginal fluid over 3 months. The pessary with 10% estriol delivered the optimal dose at 0.8 mg each week. Mechanical strength of this pessary showed no difference after emersion in simulated vaginal fluid for 3-month, supporting the long-term application. An estriol-loaded pessary was successfully developed to treat pelvic organ prolapse with sustained release of estriol over 3 months. This pessary provides promising potential to treat pelvic organ prolapse and vaginal atrophy. Nature Publishing Group UK 2022-11-21 /pmc/articles/PMC9681886/ /pubmed/36414726 http://dx.doi.org/10.1038/s41598-022-23791-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Long, Jingjunjiao
Zidan, Ghada
Seyfoddin, Ali
Tong, Stephen
Brownfoot, Fiona C.
Chowdary, Prathima
An estriol-eluting pessary to treat pelvic organ prolapse
title An estriol-eluting pessary to treat pelvic organ prolapse
title_full An estriol-eluting pessary to treat pelvic organ prolapse
title_fullStr An estriol-eluting pessary to treat pelvic organ prolapse
title_full_unstemmed An estriol-eluting pessary to treat pelvic organ prolapse
title_short An estriol-eluting pessary to treat pelvic organ prolapse
title_sort estriol-eluting pessary to treat pelvic organ prolapse
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681886/
https://www.ncbi.nlm.nih.gov/pubmed/36414726
http://dx.doi.org/10.1038/s41598-022-23791-9
work_keys_str_mv AT longjingjunjiao anestriolelutingpessarytotreatpelvicorganprolapse
AT zidanghada anestriolelutingpessarytotreatpelvicorganprolapse
AT seyfoddinali anestriolelutingpessarytotreatpelvicorganprolapse
AT tongstephen anestriolelutingpessarytotreatpelvicorganprolapse
AT brownfootfionac anestriolelutingpessarytotreatpelvicorganprolapse
AT chowdaryprathima anestriolelutingpessarytotreatpelvicorganprolapse
AT longjingjunjiao estriolelutingpessarytotreatpelvicorganprolapse
AT zidanghada estriolelutingpessarytotreatpelvicorganprolapse
AT seyfoddinali estriolelutingpessarytotreatpelvicorganprolapse
AT tongstephen estriolelutingpessarytotreatpelvicorganprolapse
AT brownfootfionac estriolelutingpessarytotreatpelvicorganprolapse
AT chowdaryprathima estriolelutingpessarytotreatpelvicorganprolapse